Exhibit 99.1

 

 

Osiris Therapeutics Reports First Quarter 2010 Financial Results

 

COLUMBIA, Md. — May 7, 2010 - Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

 

Highlights and Recent Developments

 

·                  Announced the positive interim analysis of the first 207 patients in a clinical trial evaluating Prochymal for treatment-resistant Crohn’s disease.

 

·                  Granted Orphan Drug designation from the Food and Drug Administration (FDA) for Prochymal as a treatment for type 1 diabetes.

 

·                  Achieved $1.0 million milestone from JCR Pharmaceuticals for development progress with Prochymal in Japan.

 

·                  Reported data showing Prochymal achieved a 63% response rate when used as a rescue agent in children with end-stage graft versus host disease (GvHD).

 

·                  Presented data showing Prochymal significantly improves response rates over standard of care for both liver and gastrointestinal steroid-refractory GvHD.

 

·                  Recorded net income of $2.4 million for the quarter; $0.07 per diluted common share.

 

·                  Reported cash, short-term investments and receivables of $91.2 million at March 31, 2010.

 

“We’re pleased with the progress we’ve made across many of our programs including Crohn’s disease, type 1 diabetes and GvHD,” said C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris Therapeutics.  “Given our strong balance sheet, financial discipline and practical approach to drug development, we are well-positioned to bring this first-in-class technology to the patients who need it most.”

 

First Quarter Financial Results

 

Net income for the first quarter of 2010 was $2.4 million compared to a loss from continuing operations of $7.9 million in the first quarter of 2009. Net income for the first quarter of 2009 of $14.8 million included $22.7 million of income from discontinued operations. Revenues were $11.4 million in the first quarter of 2010, consisting primarily of upfront license fees from the Genzyme agreement and a $1.0 million milestone payment achieved from our collaboration with JCR Pharmaceuticals for development progress of Prochymal in Japan. Revenues in the first quarter of 2009 were $12.7 million.  As of March 31, 2010, Osiris had $91.2 million of cash, receivables and short-term investments.

 

Research and development expenses for the first quarter of 2010 were $6.6 million, compared to $18.6 million incurred in the first quarter of 2009.  The $12.0 million decrease in R&D expenses reflects the completion of clinical work associated with our Phase III clinical trials.  General and administrative expenses were $1.8 million for the first quarter of 2010 compared to $2.9 million for the same period of the prior year.  Net cash used in continuing operations for the quarter was $10.6 million.

 

Webcast and Conference Call

 

A webcast and conference call to discuss the financial results is scheduled for today, May 7, 2010 at 9:00 am ET.  To access the webcast, visit the Investor Relations section of the company’s website at

 

 

 

 

http://investor.osiris.com/events.cfm.  Alternatively, callers may participate in the conference call by dialing (877) 303-6133 (U.S. participants) or (970) 315-0493 (international participants).

 

A replay of the conference call will be available approximately two hours after the completion of the call through May 20, 2010. Callers can access the replay by dialing (800) 642-1687 (U.S. participants) or (706) 645-9291 (international participants). The audio replay confirmation code is 72589651. To access a replay of the webcast, visit the Investor Relations section of the company’s website at http://investor.osiris.com/events.cfm.

 

About Osiris Therapeutics

 

Osiris Therapeutics, Inc. is the leading stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. The Company’s pipeline of internally developed biologic drug candidates under evaluation includes Prochymal for inflammatory, autoimmune and cardiovascular indications, as well as Chondrogen for arthritis in the knee. Osiris is a fully integrated company, with capabilities in research, development, manufacturing and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology, including 49 U.S. patents each having one or more foreign counterparts. Osiris, Prochymal and Chondrogen are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company’s website, www.Osiris.com. (OSIR-G)

 

Osiris and Genzyme formed a strategic alliance for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, Osiris retains commercialization rights to Prochymal and Chondrogen in the United States and Canada.  Genzyme holds these rights in all other countries except Japan, where JCR Pharmaceuticals holds rights to Prochymal for the treatment of patients with hematological malignancies.

 

Forward-Looking Statements

 

This press release contains forward-looking statements.  Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking.  Examples of forward-looking statements include, but are not limited to, statements regarding the following: our product development efforts; our clinical trials and anticipated regulatory requirements and the ability to successfully navigate these requirements; the success of our product candidates in development; status of the regulatory process for our biologic drug candidates; implementation of our corporate strategy; our financial performance; our product research and development activities and projected expenditures, including our anticipated timeline and clinical strategy for Prochymal, Chondrogen and our other MSC and biologic drug candidates; our cash needs; patents and proprietary rights; the safety and ability of our potential products to treat disease and the results of our scientific research; our plans for sales and marketing; our plans regarding our facilities; types of regulatory frameworks we expect will be applicable to our potential products; and results of our scientific research. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements.  Risks and uncertainties related to our Collaboration Agreement with Genzyme for the development and commercialization of Prochymal and Chondrogen include, among others:  typical business transactional risks; risks related to product development and clinical trial design, performance and completion; uncertainty of the

 

 

 

 

success of Prochymal and Chondrogen in clinical trials and their ability to treat disease; Genzyme’s early termination and opt-out rights; the ability of Osiris and Genzyme to successfully navigate regulatory requirements and to manufacture and commercialize products; and the uncertainty as to our ability to successfully perform under the collaborative arrangement and earn milestone and royalty payments thereunder.  Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the United States Securities and Exchange Commission.  Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

 

 

For additional information, please contact:

 

Erica Elchin

Osiris Therapeutics, Inc.

(443) 545-1834

OsirisPR@Osiris.com

 

Media Contacts:

Andrew Law/Rachel Gross

Schwartz Communications

(781) 684-0770

Osiris@schwartz-pr.com

 

 

 

 

 

OSIRIS THERAPEUTICS, INC.

Condensed Balance Sheets

Amounts in thousands

 

		March 31, 2010 (unaudited)			December 31, 2009
Assets
Current assets:
Cash		$	1,215		$	1,306
Short-term investments		88,588			99,409
Accounts receivable		1,389			1,138
Inventory		117			—
Prepaid expenses and other current assets		715			948
Total current assets		92,024			102,801
Property and equipment, net		3,582			3,734
Restricted cash		666			666
Other assets		340			395
Total assets		$	96,612		$	107,596
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses		$	5,794		$	9,013
Deferred revenue, current portion		40,925			41,011
Capital lease obligations, current portion		1			3
Current liabilities of discontinued operations		—			412
Total current liabilities		46,720			50,439
Deferred revenue, net of current portion		33,963			44,173
Other long-term liabilities		475			424
Total liabilities		81,158			95,036
Stockholders’ equity
Common stock, $.001 par value, 90,000 shares authorized, 32,775 shares outstanding - 2010, 32,773 outstanding - 2009		33			33
Additional paid-in-capital		273,334			272,959
Accumulated other comprehensive income (loss)		15			(88		)
Accumulated deficit		(257,928		)	(260,344		)
Total stockholders’ equity		15,454			12,560
Total liabilities and stockholders’ equity		$	96,612		$	107,596

 

 

 

 

OSIRIS THERAPEUTICS, INC.

Condensed Statements of Operations

(Unaudited)

Amounts in thousands, except per share data

 

		Three Months Ended
		March 31,
		2010			2009
Revenue from collaborative research agreements, government contract and royalties		$	11,377		$	12,726
Operating expenses:
Research and development		6,560			18,567
General and administrative		1,807			2,913
		8,367			21,480
Income (loss) from operations		3,010			(8,754		)
Other income, net		88			98
Income (loss) from continuing operations, before income taxes		3,098			(8,656		)
Income tax (expense) benefit		(682		)	748
Income (loss) from continuing operations		2,416			(7,908		)
Discontinued operations:
Income from operations of discontinued operations, net of income taxes of $117 in 2009		—			1,239
Gain from sale of discontinued operations, net of income taxes of $2,026 in 2009		—			21,428
Income from discontinued operations		—			22,667
Net income		$	2,416		$	14,759
Basic income per share
Income (loss) from continuing operations		$	0.07		$	(0.24	)
Income from discontinued operations		—			0.69
Basic earnings per share		$	0.07		$	0.45
Diluted income per share
Income (loss) from continuing operations		$	0.07		$	(0.24	)
Income from discontinued operations		—			0.69
Diluted earnings per share		$	0.07		$	0.45
Weighted Average Common Shares (basic)		32,774			32,692
Weighted Average Common Shares (diluted)		33,088			32,692

 

 

 

 

OSIRIS THERAPEUTICS, INC.

Condensed Statements of Cash Flows

(Unaudited)
Amounts in thousands

 

		Three Months Ended
		March 31,
		2010			2009
Cash flows from operating activities:
Continuing operations
Income (loss) from continuing operations		$	2,416		$	(7,908	)
Adjustments to reconcile income (loss) from continuing operations to net cash used in operations:
Depreciation and amortization		190			127
Non cash share-based payments		374			1,018
Changes in operating assets and liabilities:
Accounts receivable		(251		)	246
Prepaid expenses and other current assets		116			254
Other assets		55			156
Accounts payable and accrued expenses		(3,168		)	1,796
Deferred revenue		(10,296		)	(10,092		)
Net cash used in continuing operations		(10,564		)	(14,403		)
Discontinued operations
Income from discontinued operations		—			22,667
Adjustments to reconcile income from discontinued operations to net cash used in discontinued operations:
Non cash impact of the sale of discontinued operations		—			(14,121		)
Depreciation and amortization		—			210
Non cash share-based payments		—			125
Changes in operating assets and liabilities:
Accounts receivable		—			(17,214		)
Inventory and other current assets		—			1,707
Accounts payable and accrued expenses		(412		)	4,261
Net cash used in discontinued operations		(412		)	(2,365		)
Net cash used in operating activities		(10,976		)	(16,768		)
Cash flows from investing activities:
Purchases of property and equipment		(38		)	(35		)
Proceeds from the sale of property and equipment		—			17
Proceeds from sale of discontinued operations, net		—			9,870
Proceeds from sale of investments available for sale		11,097			11,806
Purchases of investments available for sale		(173		)	—
Net cash provided by investing activities		10,886			21,658
Cash flows from financing activities:
Principal payments on capital lease obligations and notes payable		(2		)	(2		)
Restricted cash		—			(536		)
Proceeds from the issuance of common stock, net		1			134
Net cash used in financing activities		(1		)	(404		)
Net (decrease) increase in cash		(91		)	4,486
Cash at beginning of period		1,306			940
Cash at end of period		$	1,215		$	5,426